SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : EntreMed (ENMD) -- Ignore unavailable to you. Want to Upgrade?

To: Cage Rattler who wrote (1337)10/27/1998 4:19:00 PM
From: tommysdad  Read Replies (1) | Respond to of 2135
 
CarboMed is not listed, as far as I can tell.

The full article is available at:

pnas.org

If the data hold up, this seems like a reasonable target for ENMD. I have to wonder at the timing of this paper -- if CarboMed is smart, they will have already filed a patent claiming anti-angiogenesis approaches to treating spinal cord injuries. If not, they're going to get their butts kicked ---- too many angiogenesis programs out there.


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News